Rheumatoid Arthritis Treatment Market to Record an Exponential CAGR 6% by 2021 - 2031

The Rheumatoid Arthritis Treatment Market is expected to reach US$ 40.5 Bn at a CAGR of 6% from 2021-2031. Tech-driven innovation is the trend that the healthcare vertical would be resting on in the forecast period. With precision medicine being the focal point, extensive research is being carried out in every arm of the healthcare vertical.

In 2020, approximately 4.9 million individuals across major regions were affected by rheumatoid arthritis. Manufacturers are focusing on partnerships and expansion of product portfolio by launching technologically advanced products and receiving approval from different government bodies.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/22555

The global rheumatoid arthritis treatment market is estimated to be valued at US$ 40.5 Bn in 2021 and is expected to exhibit a CAGR of around 6% over the forecast period (2021 – 2031).

Key Take aways from Market Study

Under therapy, DMARDs hold maximum value share, owing to increasing awareness associated with their utilization.

By distribution channel, hospital pharmacies hold a notable revenue share of more than 75% in the market.

The market North America accounted for a share of over 40% in 2020 and is expected to experience significant growth over the next ten years.

Europe is the next dominating region with a market share of 28% in 2020, due to well-developed healthcare infrastructure largely supported by the government.

“Rise in prevalence of rheumatoid arthritis along with an increase in adoption of DMARD therapies, flourishing combination treatment, and supportive government policies are expected to drive market growth,” says a Persistence Market Research analyst.

Get To Touch in our Expert @ https://www.persistencemarketresearch.com/ask-an-expert/22555

Collaborations and Acquisitions – Imperative Strategy for Market Players

Major companies in the rheumatoid arthritis treatment market are actively engaging in acquisitions and expansions in order to enhance their product portfolios and outreach to a large number of customers. Globally, leading companies are acquiring other companies who are facing a large number of product recalls in the market.

In April 2021, Novartis signed an initial agreement with Roche to reserve capacity and implement technology transfer for the production of active pharmaceutical ingredient (API) for Roche’s Actemra/RoActemra® (tocilizumab), a treatment for rheumatoid arthritis, which is also being tested in various clinical trials investigating the safety and efficacy in COVID-19-associated pneumonia.

In October 2020, Johnson & Johnson announced the successful acquisition of Momenta Pharmaceuticals, Inc. (“Momenta”), a company that discovered and developed novel therapies for immune-mediated diseases.

COVID-19 Crisis Impact-

The World Health Organization (WHO) declared the COVID-19 outbreak a public health emergency of international significance on January 30, 2020. Around 210 countries have been affected by COVID-19. Patients with rheumatoid arthritis who contract COVID-19 infection, according to the Lancet Rheumatology 2020, are at a high risk of experiencing serious symptoms and complications.

Some DMARDs commonly used to treat rheumatoid arthritis, such as hydroxychloroquine drugs, are being investigated as a potential therapy for COVID-19. Moreover, other generally used therapies such as biologics targeting interleukin (IL)-6 (sarilumab, tocilizumab) and IL-1 (anakinra) are being assessed in patients with COVID-19. Thus, COVID-19 infection uplifted growth opportunities for manufacturers of rheumatoid arthritis drugs.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/22555

For instance, Tocilizumab, a drug originally used for rheumatoid arthritis, is seeing increased use in treating severe COVID-19 patients.

A drug developed for rheumatoid arthritis by global pharma company Roche is licensed exclusively to Indian pharma company Cipla.

What else is in the report?

Persistence Market Research offers a unique perspective and actionable insights on the rheumatoid arthritis treatment market in its latest study, presenting a historical demand assessment of 2016 – 2020 and projections for 2021–2031, based on therapy (symptomatic treatment, intermediate corticosteroid therapies, stem cell therapy/ cell therapy, and disease-modifying anti-rheumatic drugs (DMARDs)) and distribution channel (hospital pharmacies, retail pharmacies, and drug stores), across seven key regions of the world.

PMR Exclusive Reports-

Medical Marijuana Market: https://www.persistencemarketresearch.com/market-research/medical-marijuana-market.asp

Mitotane Market: https://www.persistencemarketresearch.com/market-research/mitotane-market.asp

Insomnia Treatment Market: https://www.persistencemarketresearch.com/market-research/insomnia-treatment-market.asp

Pulmonary Fibrosis Treatment Market: https://www.persistencemarketresearch.com/market-research/pulmonary-fibrosis-treatment-market.asp

Contact us:

Persistence Market Research
Address – 305 Broadway, 7th FloorNew York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com

About Us-

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers’ experience by acting as the “missing” link between “customer relationships” and “business outcomes’. The best possible returns are assured therein.

This release was published on openPR.